Drug intelligence / Profile preview

paclitaxel + anthracycline + cyclophosphamide

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of paclitaxel, an anthracycline (such as epirubicin or doxorubicin), and cyclophosphamide. This regimen is primarily used in the treatment of breast cancer, leveraging the different mechanisms of action of these three agents to provide effective anti-tumor activity. The combination can be administered sequentially or concurrently, and dosing schedules vary across different protocols.

Other names: paclitaxel plus doxorubicin or epirubicin plus cyclophosphamidetaxane-anthracycline-cyclophosphamide regimen

Targets

TOP2A (DNA topoisomerase II)MicrotubuleDNA

Beyond the preview

Go deeper on paclitaxel + anthracycline + cyclophosphamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paclitaxel + anthracycline + cyclophosphamide.

Explore the full profile